Chester County News and Community Website
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76. This experimental treatment is a …
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Andy Pasternak as Chairman of its Board of Directors, following the departure of Richard Berman, who stepped down …
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, has reported its financial results for the third quarter ending September 30, 2024, alongside significant corporate milestones. The …
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) is gearing up for a series of key investor conferences scheduled for November 2024, where the company aims to share insights and updates …
Context Therapeutics to Engage Investors at November Conferences Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced that its innovative cancer therapy, CTIM-76, will be featured at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting …
Context Therapeutics to Showcase Promising Cancer Therapy at SITC Annual Meeting Read More SAN DIEGO, CA and PHILADELPHIA, PA — BioAtla, Inc. and Context Therapeutics Inc. have entered into a significant agreement, granting Context an exclusive, worldwide license to develop and commercialize BioAtla’s BA3362, …
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the addition of two industry veterans, Dr. Karen Smith and Dr. Luke Walker, to its Board of Directors. This strategic move …
Context Therapeutics Strengthens Board with Key Appointments Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced its financial results for the second quarter ended June 30, 2024, along with recent business highlights.
Context Therapeutics Shines Bright: Q2 Successes and Promising Future Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer, and Karen Andreas, M.S. as Vice President of Clinical …
Context Therapeutics Appoints New Chief Medical Officer and VP of Clinical Operations Read More PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced a significant addition to its drug pipeline with the acquisition of CT-95 from Link Immunotherapeutics, Inc. The asset is a mesothelin …
Context Therapeutics Acquires Promising Cancer Treatment Asset Read More